Complex diseases are multi‑pathway. Single‑target drugs miss the mark.
In a large majority of diseases, multiple interconnected pathways drive disease progression. Traditional drugs usually hit a single target, so they can’t keep pace with the complexity. The result: only partial therapeutic benefit, significant side effects, and 40–50% of clinical drug failures caused by insufficient efficacy. Genetic medicines promised more, but they’ve struggled too. Existing delivery systems can’t reliably reach the right tissues, therapeutic cargos are often limited to one target, and manufacturing is complex and expensive.
That’s where SymphoRNA comes in.
We've proven what others could not - reliable, targeted delivery of multiple RNAs is achievable within the same system.
Hover over to learn more
Then we built the therapeutic engine to unlock its full potential. We can combine mRNAs and siRNAs to not just finely tune previously “undruggable” pathways, but we bring together the targets synergistically to make the therapeutic value stronger than ever before.
IPF
We’re starting with idiopathic pulmonary fibrosis. When the stakes are high, complexity doesn’t scare us—we’re built for it.
3M
People affected with IPF globally
3-5
Years median survival rate post-diagnosis
$4B
Market size in 2024 with only two approved treatments. The market is expected to nearly double by 2034.
Our unique RNA technology targets multiple disease pathways simultaneously with a single administration. We are currently focusing on four different pathways including some never used before!
Our data shows it clearly: combinations beat single targets.
3 targets together (purple, represented by a shift to the right) compared to control (green) and the siRNA alone (blue) for a key IPF target.